Evidence map›Paper›PMID 39091917›Full record

ReviewFrontiers in oncology2024

Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.

Domenico Ribatti, Gerardo Cazzato, Roberto Tamma, Tiziana Annese, Giuseppe Ingravallo, Giorgina Specchia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Domenico RibattiDepartment of Translational Biomedicine and Neuroscience, University of Bari Medical School, Bari, Italy.
Gerardo CazzatoDepartment of Precision and Regenerative Medicine and Ionian Area, University of Bari Medical School, Bari, Italy.
Roberto TammaDepartment of Translational Biomedicine and Neuroscience, University of Bari Medical School, Bari, Italy.
Tiziana AnneseDepartment of Translational Biomedicine and Neuroscience, University of Bari Medical School, Bari, Italy.
Giuseppe IngravalloDepartment of Precision and Regenerative Medicine and Ionian Area, University of Bari Medical School, Bari, Italy.
Giorgina SpecchiaDepartment of Precision and Regenerative Medicine and Ionian Area, University of Bari Medical School, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-Hodgkin lymphomas (NHLs) encompass a diverse group of malignancies arising from B cells, T cells, and natural killer (NK) cells at various stages of differentiation. Conversely, classical Hodgkin lymphomas (cHLs) primarily feature Reed-Sternberg cells (RSCs) amid a background of reactive immune cells. Immunomodulatory pathways, notably the PD-1/PD-L1 axis, play pivotal roles in tumor immune evasion across both NHLs and cHLs. Elevated expression of PD-1 and PD-L1 is observed in a spectrum of lymphomas, influencing prognosis and treatment response. Therapeutically, immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have revolutionized lymphoma management, particularly in relapsed/refractory cases. Nivolumab and pembrolizumab, among others, have demonstrated efficacy in various B-cell lymphomas, with promising outcomes in cHL. Combination strategies incorporating ICIs with conventional chemotherapy or targeted agents show enhanced efficacy and are being explored extensively. In this review we discuss the most important features of the tumor microenvironment of NHLs and cHLs, address the therapeutic approaches with ICIs and try to outline future perspectives.

Indexed as

Hodgkin lymphomaimmune checkpoint inhibitorsnon-Hodgkin lymphomaPD-1/PD-L1therapy

Identifiers

PMID39091917
PMCPMC11291367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.